www.mydario.com OTCQB: DRIO This presentation of LabStyle - - PowerPoint PPT Presentation

mydario com otcqb drio
SMART_READER_LITE
LIVE PREVIEW

www.mydario.com OTCQB: DRIO This presentation of LabStyle - - PowerPoint PPT Presentation

www.mydario.com OTCQB: DRIO This presentation of LabStyle Innovations Corp. (the Company ) and statements of the Company s management or agents related thereto contain or may contain forward-looking statements within the meaning of the


slide-1
SLIDE 1

www.mydario.com

slide-2
SLIDE 2

www.mydario.com

OTCQB: DRIO

This presentation of LabStyle Innovations Corp. (the “Company”) and statements of the Company’s management or agents related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate“, ‘will”, “would” and other similar expressions all denote forward-looking statements within the meaning of the

  • Act. Factors that could cause or contribute to such differences include the Company’s compliance with regulatory

requirements, the Company’s status as a new public company, the impact of current and any future competition, as well as other factors and risks discussed in the Company's filings (including the results of the company’s commercial and regulatory plans for Dario™) with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or

  • therwise, except as required by applicable law.

In addition, readers are cautioned that any estimates, forecasts or projections contained in this presentation or as may be discussed by Company management or its agents have been prepared by Company management in good faith on a basis believed to be reasonable. However, such estimates, forecasts and projections involve significant elements of subjective judgment and analysis and no representation can be made as to their attainability. No representation or warranty (express or implied) is made or is to be relied upon as a promise or representation as to the future performance of the Company. Readers are cautioned that such estimates, forecasts or projections have not been audited and have not been prepared in conformance with generally accepted accounting principles.

slide-3
SLIDE 3

www.mydario.com

OTCQB: DRIO

slide-4
SLIDE 4

www.mydario.com

OTCQB: DRIO

slide-5
SLIDE 5

www.mydario.com

OTCQB: DRIO

Soft Launch (UK/NZ)

Q3/14 Q4/14 Q1/15 Q2/15 Q3/15

Australia Netherland Canada

USA

Reimbursement received

Italy Costa Rica Panama

slide-6
SLIDE 6

www.mydario.com

OTCQB: DRIO

slide-7
SLIDE 7

www.mydario.com

OTCQB: DRIO

slide-8
SLIDE 8

www.mydario.com

OTCQB: DRIO

Glucose Monitoring, $12bn Therapy - Insulin, $54bn

(Source: International Diabetes Federation)

slide-9
SLIDE 9

www.mydario.com

OTCQB: DRIO Tool/Medicine Behavioral Change Support

24/7

slide-10
SLIDE 10

www.mydario.com

OTCQB: DRIO

Social Network Dario 24/7 Support Dario Mobile Solution

Dario Mobile Management Platform Clinical Program Library Daily feedback to adjust and optimize treatment

slide-11
SLIDE 11

www.mydario.com

OTCQB: DRIO

Personalized Treatment Decision support Overall Diabetes Management

slide-12
SLIDE 12

www.mydario.com

OTCQB: DRIO

25 Strip Cartridge – GOD technology Smart Meter plugs into smart mobile devices (one device iOS + Android) Lancing device

 Co Compact  Tin Tiny bl bloo

  • od sam

ample le  Highl Highly acc accurate  iOS/ OS/Androi

  • id  Ine

nexpensiv ive  High ghly ly usab usable le - No No ba battery ry  CE CE Mar Mark gr granted in n Sep September 2013 2013  Pot

  • tentia

ial l 2015 2015 FD FDA A app approval l

slide-13
SLIDE 13

www.mydario.com

OTCQB: DRIO

  • Easier monitoring
  • Remote support
  • Auto alerts

Patient

Supporters

Payers

  • Online patient monitoring
  • Improve compliance
  • Reduce healthcare costs
slide-14
SLIDE 14

www.mydario.com

OTCQB: DRIO

Company Basic Feature BGM (Freestyle, Verio, Contour, Aviva etc.) BGM for Insulin Users (Aviva Expert, Insulinx) All-in one (Roche Accu- Chek Mobile) Smartphone Connected (iBGStar, iHealth Align, 2in1) Cellular connectivity (Liveongo, Telcare)

All-in-one Kit

     

Pocket sized

     

Powerless

     

iOS/Android

   /  

Information sharing with doctors and relatives

     

Actionable insights

/    / 

Insulin recommendation

     

Estimated HBA1C

     

Community platform

     

Mentor platform

    / 

Clinical Programs

    / 

Pricing

      Device Disease Management

slide-15
SLIDE 15

www.mydario.com

OTCQB: DRIO

Disease management Dedicated Device Smartphone Compatible

Hardware

Logger

Software

iOS/android compatibility limitations

slide-16
SLIDE 16

www.mydario.com

OTCQB: DRIO

  • 85% reimbursement & out of pocket
  • Disposable strips (recurring revenue

model)

  • Service fees for behavioral programs

improving clinical outcome

  • Meta analysis for Payers and HMO’s
  • Insurers online monitoring
  • Clinical studies platform
  • Tele-care providers
slide-17
SLIDE 17

www.mydario.com

OTCQB: DRIO

$0 $100 $200 $300 $400 $500 $600 0.1% 0.2% 0.5% 1.0% 2.0% Data Monitization Behavioral programs Monitoring

slide-18
SLIDE 18

www.mydario.com

OTCQB: DRIO

Distributors sales force to drive sales through healthcare professionals (GP’s) Labstyle Innovations - Direct online marketing, email, App, Facebook, SEO

Prescription / Reimbursement

B2B B2C

slide-19
SLIDE 19

www.mydario.com

OTCQB: DRIO

slide-20
SLIDE 20

www.mydario.com

OTCQB: DRIO

slide-21
SLIDE 21

www.mydario.com

OTCQB: DRIO

slide-22
SLIDE 22

www.mydario.com

OTCQB: DRIO

slide-23
SLIDE 23

www.mydario.com

OTCQB: DRIO

Name Experience

Headquarters

Erez Raphael Acting Chairman and CEO

  • 20 years of experience in building product organizations – from Design to

commercialization.

  • Formerly with Amdocs (NYSE: DOX) and Nokia-Siemens.

Israel

Zvi Ben-David CFO

  • 25 years of experience with public and private medical device companies
  • CFO of Given Imaging Ltd. (formerly Nasdaq: GIVN), and UltraShape Medical

Ltd. Israel

Bill McGrill, RAC VP Regulatory

  • 25 years of experience in the medical device industry.
  • Experienced in new product development and regulatory affairs for clearance
  • f medical products in the U.S., European Union, Canada and a number of
  • ther foreign markets

U.S.

David Edelman Director Product Strategy

  • Entrepreneur and patient advocate who has dedicated his career to using

technology to improve health and happiness.

  • President of Diabetes Daily, a leading online community and educational

platform. U.S.

Eran Kurman VP, Global Strategy

  • 16 years of executive leadership in the Medical Device Industry.
  • Extensive experience in global strategic marketing, business development,

and clinical development knowledge. Israel

Dror Bacher VP R&D

  • 15 years of software business experience
  • Managing product development at mobile and semi-conductor companies.

Israel

slide-24
SLIDE 24

www.mydario.com

OTCQB: DRIO

Name Experience

Prof Itamar Raz, MD Head of SAB

  • Head of Diabetes Unit and Research Center, Hadassah Medical Center
  • Israel National Council of Diabetes of the Israel Ministry of Health
  • President, Israel Diabetes Research Group.

Gary Scheiner, CDE MS

  • Type 1 diabetes since 1985 acknowledged as the 2014 Diabetes Educator of the Year by the

American Association of Diabetes Educators.

  • Known for his globally-available coaching services at IntegratedDiabetes.com.
  • Dr. William Polonsky, PhD
  • An internationally recognized expert in the behavioral aspects of diabetes management.
  • Co-founded the Behavioral Diabetes Institute Author of numerous books on Diabetes.

Hope Warshaw, MMSc RD CDE BC-ADM

  • Dietitian and diabetes educator for nearly thirty-five years.
  • Owner of consulting practice, for corporate consulting to consumer and professional writing and

individual diabetes and weight management counseling.

  • Dr. Paul Rosman

DO FACP FACE FACOI

  • Former Senior Medical Advisor at Eli Lilly, held teaching positions at Ohio University and

Northeastern Ohio Universities College of Medicine

  • Former President or Chair of American Diabetes Association, American Association of Clinical

Endocrinologists, and the Ohio Diabetes Prevention and Control Program

  • Dr. Paolo Pozzilli, MD
  • Professor of Endocrinology and Metabolic Diseases,
  • Head of Department at the University Campus Bio-Medico in Rome, Italy
  • Professor of Diabetes Research at St. Bartholomew’s and the London School of Medicine.
  • Dr. Eberhard Standl,MD
  • Professor of Medicine, Endocrinologist and Angiologist at the Munich Diabetes Research Group in
  • Germany. Has developed his career in both Munich, and at the Joslin Diabetes Center in Boston.
slide-25
SLIDE 25

www.mydario.com

OTCQB: DRIO